AbbVie | ABBV - Capitaux Propres Et Réserves





Capitaux Propres Et Réserves Changement Date
AbbVie USD -6.66B 3.39B 2026-03
Abbott USD 52.06B 69M 2026-03
ALKERMES USD 1.75B 67.76M 2026-03
Amgen USD 9.19B 532M 2026-03
AstraZeneca USD 47.33B 1.33B 2026-03
Biogen USD 18.65B 394.9M 2026-03
BioMarin Pharmaceutical USD 6.21B 125.11M 2026-03
Bristol-Myers Squibb USD 20.07B 1.6B 2026-03
Coherus Biosciences USD 61.01M 26.76M 2025-12
Eisai JPY 898.99B 9.36B 2026-03
Eli Lilly USD 31.2B 4.66B 2026-03
Gilead Sciences USD 23.52B 897M 2026-03
GlaxoSmithKline GBP 17.42B 1.05B 2026-03
J&J USD 81.19B 358M 2026-03
Medtronic USD 48.99B 128M 2025-12
Merck USD 45.88B 6.73B 2026-03
Neurocrine Biosciences USD 3.41B 154.3M 2026-03
Novartis USD 38.93B 7.2B 2026-03
Pacira USD 653.89M 39.22M 2026-03
Perrigo USD 2.5B 436.7M 2026-03
Pfizer USD 90.1B 3.63B 2026-03
Regeneron Pharmaceuticals USD 31.42B 166.7M 2026-03
Roche Holding CHF 33.8B 758M 2025-12
Sanofi EUR 72.81B 1.1B 2026-03
UCB EUR 10.87B 1.18B 2025-12
Ultragenyx Pharmaceutical USD -236M 156M 2026-03
United Therapeutics USD 5.9B 1.2B 2026-03
Vertex Pharmaceuticals USD 19.36B 696.1M 2026-03
Zoetis USD 3.23B 98M 2026-03